From CNBC: 2024-05-10 07:00:01

The FDA delays approval of Moderna’s RSV vaccine to end of May due to administrative constraints. Decision expected Sunday, no safety concerns raised. Second product launch in U.S. after Covid shot, third RSV vaccine in market. CDC panel to review shot use and population on June 26-27. Vaccine tested in older adults to prevent severe RSV cases. Investors optimistic about Moderna’s mRNA product pipeline. Shares up 20% this year after 45% decline in 2023.



Read more at CNBC: Moderna says RSV vaccine FDA approval delayed to end of May